Faruqi & Faruqi Investigates Soleno Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 22 2026
0mins
Should l Buy SLNO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Soleno Therapeutics, focusing on investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, to assess potential legal claims.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Contact Information Provided: Investors who have suffered losses are encouraged to contact Faruq & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Securities Law Firm Role: As a leading national securities law firm, Faruq & Faruqi is committed to providing legal support to investors, ensuring their rights are upheld in securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.440
Low
75.00
Averages
110.50
High
125.00
Current: 30.440
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Disclosures
- Class Action Initiated: A securities class action lawsuit has been filed against Soleno Therapeutics (NASDAQ:SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a 26% drop in share price triggered by disappointing DCCR drug information released on November 5.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno misrepresented safety issues related to DCCR, particularly concerning fluid retention risks, misleading investors about the drug's commercial viability and impacting the company's market performance.
- Severe Market Reaction: Since August 15, 2025, Soleno's stock has plummeted nearly 40%, primarily due to concerns raised by activist short seller Scorpion Capital regarding the drug's potential market withdrawal risks, exacerbating investor panic.
- Potential Legal Consequences: Hagens Berman is investigating whether Soleno violated federal securities laws, and if confirmed, the company could face severe legal repercussions and financial losses as a result of misleading investors.
See More
Soleno Therapeutics Class Action Reminder for Investors
- Lawsuit Background: Soleno Therapeutics faces allegations regarding safety issues with its DCCR drug, resulting in significant investor losses during the period from August to November 2025, with stock prices dropping by 11.98%, 19.21%, and 26.59% respectively.
- Stock Price Volatility: On August 18, 2025, Soleno's stock fell by $9.27 due to negative reports, followed by a further decline of $13.49 on September 11 after a patient death, highlighting severe market concerns over the product's safety.
- Legal Allegations: The class action lawsuit claims that Soleno failed to disclose safety risks associated with DCCR throughout the class period, misleading investors about the company's prospects and affecting their investment decisions.
- Investor Action: Investors are urged to file a lead plaintiff motion by May 5, 2026, to seek compensation for losses incurred from Soleno stock investments, emphasizing the urgency of legal action.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Soleno Therapeutics and certain executives, seeking damages for investors who purchased Soleno securities between March 26, 2025, and November 4, 2025.
- Insufficient Safety Disclosure: The complaint alleges that Soleno failed to adequately disclose significant safety concerns related to its DCCR clinical trial, including issues of fluid retention in participants, which misled investors about the true risks associated with the drug.
- Commercial Viability Risks: The undisclosed safety risks raise serious questions about DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions, which could severely impact the company's reputation and legal standing.
- Investor Action Recommendations: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to participate in any recovery, with the law firm operating on a contingency fee basis, thereby minimizing financial risk for investors.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Timeline: Investors who purchased common stock of Soleno Therapeutics (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, should note that the deadline to apply as lead plaintiff is May 5, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention, leading to investor losses when the true information was revealed, thereby impacting the company's reputation and market trust.
- Legal Counsel Selection: Investors are advised to choose legal counsel with a proven track record; Rosen Law Firm has excelled in securities class actions, having been ranked No. 1 by ISS in 2017, showcasing its expertise and resource advantages in this field.
- Potential Compensation Mechanism: Investors participating in the class action can receive compensation without any upfront costs through a contingency fee arrangement, providing a risk-free avenue for affected investors to seek redress and enhancing their confidence in the process.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating Soleno Therapeutics, focusing on investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, to assess potential legal claims.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers for discussions on legal options, demonstrating a commitment to client support.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Soleno's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Soleno Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics (NASDAQ: SLNO) is facing a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks that could impact stock price and market trust.
- Key Allegations: The lawsuit alleges that the company made materially false statements and omissions regarding its DCCR drug's Phase 3 clinical trial, particularly failing to disclose safety concerns, which could lead to severe misjudgments about the company's future business prospects by investors.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to the revelation of negative information related to DCCR, reflecting market concerns over the company's operational transparency and potential financial losses.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities the company may face in the legal proceedings and the implications for investors.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over DCCR Disclosures
- Class Action Initiated: A securities class action lawsuit has been filed against Soleno Therapeutics (NASDAQ:SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a 26% drop in share price triggered by disappointing DCCR drug information released on November 5.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno misrepresented safety issues related to DCCR, particularly concerning fluid retention risks, misleading investors about the drug's commercial viability and impacting the company's market performance.
- Severe Market Reaction: Since August 15, 2025, Soleno's stock has plummeted nearly 40%, primarily due to concerns raised by activist short seller Scorpion Capital regarding the drug's potential market withdrawal risks, exacerbating investor panic.
- Potential Legal Consequences: Hagens Berman is investigating whether Soleno violated federal securities laws, and if confirmed, the company could face severe legal repercussions and financial losses as a result of misleading investors.
See More
Soleno Therapeutics Class Action Reminder for Investors
- Lawsuit Background: Soleno Therapeutics faces allegations regarding safety issues with its DCCR drug, resulting in significant investor losses during the period from August to November 2025, with stock prices dropping by 11.98%, 19.21%, and 26.59% respectively.
- Stock Price Volatility: On August 18, 2025, Soleno's stock fell by $9.27 due to negative reports, followed by a further decline of $13.49 on September 11 after a patient death, highlighting severe market concerns over the product's safety.
- Legal Allegations: The class action lawsuit claims that Soleno failed to disclose safety risks associated with DCCR throughout the class period, misleading investors about the company's prospects and affecting their investment decisions.
- Investor Action: Investors are urged to file a lead plaintiff motion by May 5, 2026, to seek compensation for losses incurred from Soleno stock investments, emphasizing the urgency of legal action.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Soleno Therapeutics and certain executives, seeking damages for investors who purchased Soleno securities between March 26, 2025, and November 4, 2025.
- Insufficient Safety Disclosure: The complaint alleges that Soleno failed to adequately disclose significant safety concerns related to its DCCR clinical trial, including issues of fluid retention in participants, which misled investors about the true risks associated with the drug.
- Commercial Viability Risks: The undisclosed safety risks raise serious questions about DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions, which could severely impact the company's reputation and legal standing.
- Investor Action Recommendations: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to participate in any recovery, with the law firm operating on a contingency fee basis, thereby minimizing financial risk for investors.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Timeline: Investors who purchased common stock of Soleno Therapeutics (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, should note that the deadline to apply as lead plaintiff is May 5, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention, leading to investor losses when the true information was revealed, thereby impacting the company's reputation and market trust.
- Legal Counsel Selection: Investors are advised to choose legal counsel with a proven track record; Rosen Law Firm has excelled in securities class actions, having been ranked No. 1 by ISS in 2017, showcasing its expertise and resource advantages in this field.
- Potential Compensation Mechanism: Investors participating in the class action can receive compensation without any upfront costs through a contingency fee arrangement, providing a risk-free avenue for affected investors to seek redress and enhancing their confidence in the process.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating Soleno Therapeutics, focusing on investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, to assess potential legal claims.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers for discussions on legal options, demonstrating a commitment to client support.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Soleno's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Soleno Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics (NASDAQ: SLNO) is facing a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks that could impact stock price and market trust.
- Key Allegations: The lawsuit alleges that the company made materially false statements and omissions regarding its DCCR drug's Phase 3 clinical trial, particularly failing to disclose safety concerns, which could lead to severe misjudgments about the company's future business prospects by investors.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to the revelation of negative information related to DCCR, reflecting market concerns over the company's operational transparency and potential financial losses.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities the company may face in the legal proceedings and the implications for investors.
See More
